ARVO 2018: Port Delivery System Designed to Reduce Burden of Lucentis Injections for Wet AMD
Eye On the Cure Research News
Dr. Christopher Brittain, Genentech medical director, discusses his company’s port delivery system, a tiny capsule implanted into the eye, for delivery of Lucentis® over a period of a few months.
Dr. Christopher Brittain, Genentech medical director, discusses his company's port delivery system, a tiny capsule implanted into the eye, for delivery of Lucentis® over a period of a few months. The device is currently in a Phase 2 clinical trial. The image on the right shows the port implanted into an eye.
